Skip to main content

Table 1 Patients’ demographic and baseline characteristics (n = 13)

From: Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study

Age (years), median (IQR) 64 (50–68)
Gender, n (%)
 Male 2 (15.4)
 Female 11 (84.6)
Type of AIT, n (%)
 SLIT 13 (100)
Target of AIT, n (%)
 Cedar pollen 11 (84.6)
 Mite 2 (15.4)
Concomitant asthma, n (%) 1 (7.7)
Concomitant RADs, n (%)
 RA 8 (61.5)
 Other RADs 5 (38.5)
Disease duration of RADs (year), median (IQR) 7.6 (6.7–10.5)
Positive for anti-CCP antibodies, a n (%) 5 (62.5)
Positive for rheumatoid factor, a n (%) 6 (75)
Glucocorticoid use, n (%) 3 (23)
 Dose(mg/day), b median (IQR) 1 (0.88–2.5)
Methotrexate use, n (%) 4 (30.7)
 Dose(mg/day), b median (IQR) 6 (5.75–6.5)
Other immunosuppressants use, n (%) 2 (15.3)
Immunomodulators use, n (%) 2 (15.3)
Biologics use, n (%) 6 (46.1)
  1. Other RADs consisted of 1 case of polymyositis with systemic sclerosis, 1 case of Sjogren’s syndrome, 1 case of eosinophilic granulomatosis with polyangiitis, 1 case of peripheral spondyloarthritis, and 1 case of diffuse fasciitis without eosinophilia
  2. The other immunosuppressants were tacrolimus and azathioprine. Immunomodulators were sulfasalazine and bucillamine. Biologics were golimumab, abatacept, and tocilizumab
  3. AIT, Allergen immunotherapy; SLIT, sublingual immunotherapy; RA, Rheumatoid arthritis; RADs, Rheumatic autoimmune diseases; CCP, cyclic citrullinated peptide
  4. aThe rates of rheumatoid factor and anti CCP antibody were calculated for the population of rheumatoid arthritis patients
  5. bMedian glucocorticoid and methotrexate dose were calculated among each agent users